triple agonist retatrutide Obesity Targeting Glp-1 Stock Photo 2639191569 Today, we shared new data

As with other incretin-based therapies, the most commonly reported adverse effects in the retatrutide phase 2 trial were gastrointestinal in nature

This guide breaks down every meaningful difference between these three medications, with specific numbers from clinical trials, practical dosing information, and honest guidance about who should consider each option

[5] You get the best results from either medication by following your treatment plan alongside long-term lifestyle changes, including a healthy diet and increased physical activity

Over time, insulin sensitivity improves, inflammation decreases, and appetite regulation becomes more stable

And if you don't eat, you lose weight

Baseline bloodwork should be completed before the first injection